AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Lokelma (sodium zirconium cyclosilicate) by Quarter
Lokelma (sodium zirconium cyclosilicate) — Established RoW YoY actual (%) (%)
AstraZeneca Lokelma (sodium zirconium cyclosilicate): 12.0% in Q2 2026, down 18.0 pts from a year earlier. That is the lowest of the 17 quarters on record here.
Where the Q2 2026 figure comes from
“|| Lokelma | 221 | | 26 | | 26 | | 85 | | 13 | | 48 | | 47 | | 40 | | 47 | | 54 | | 46 | | 41 | | 12 | | 22”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lokelma (sodium zirconium cyclosilicate) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 12.0% | -18.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 23.0% | +1.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 24.0% | -4.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 37.0% | +19.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 30.0% | +14.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 22.0% | +6.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 28.0% | -3.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 18.0% | -13.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 16.0% | -18.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 16.0% | -13.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 31.0% | +13.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 31.0% | 0.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 34.0% | -44.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | 29.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | 18.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | 31.0% | – | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 78.0% | – | Form 6-K FY2022Q2 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Lokelma (sodium zirconium cyclosilicate) (%), quarterly Q2 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-lokelma-erow-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.
See a number that looks wrong?